BSG 2025 HCC Guidelines: NHS-Tailored Roadmap for Frontline Clinicians
Pragmatic Algorithm, Surveillance Clarity, Bleeding Risk Management & Equity in UK Liver Cancer Care
A Turning Point for UK HCC Care
Hepatocellular carcinoma (HCC) incidence in the UK has doubled in the last decade, with over 7,000 new cases annually and mortality climbing in parallel with NASH, alcohol, and viral hepatitis. The British Society of Gastroenterology (BSG) has responded with a 2025 guideline update — published in Frontline Gastroenterology — that is not a global rehash, but an NHS-optimized playbook for frontline clinicians.
Led by Dr. Abid Suddle and the HCC-UK committee, this document distills global evidence into local action, addressing four critical gaps: surveillance, treatment access, bleeding risk in immunotherapy, and equity.
BSG 2025: Four Pillars of Change
- Surveillance Clarity: Who to scan, who to stop
- NHS Algorithm: Decision tree for every tumor size
- Immunotherapy Safety: Variceal management before bevacizumab
- Equity & Access: Regional MDTs, nurse-led clinics, GP surveillance
The BSG 2025 Treatment Algorithm (Official Chart)
BSG HCC Management Algorithm 2025
Source: Suddle et al., Frontline Gastroenterology 2025 | Reproduced with permission
1. Surveillance: Who to Scan, Who to Stop
| Group | Imaging | Frequency | Notes |
|---|---|---|---|
| Cirrhosis (any cause) | US ± AFP | Every 6 months | Continue if PS 0–2 |
| Chronic HBV (high-risk) | US ± AFP | Every 6 months | Even without cirrhosis |
| Child-Pugh C (non-LT) | STOP | N/A | Risk > benefit |
"AFP is recommended with ultrasound in high-risk groups, especially in obesity/NASH where US sensitivity is reduced." — BSG 2025
2. Early-Stage HCC: Resection vs Ablation vs Transplant
| Tumor | Child-Pugh | 1st Line | Alternative |
|---|---|---|---|
| Solitary <2 cm | A/B | Ablation = Resection | Transplant (Milan) |
| Solitary 2–5 cm | A | Resection | Transplant / TACE+SABR |
| Solitary 5–7 cm | A | Transplant (after downstaging) | TACE / SIRT |
| Multifocal (within LT) | A/B | Transplant | Ablation / TACE |
3. Advanced HCC: Immunotherapy + Bleeding Risk Framework
First-Line (BCLC C, PS 0–1, Child A/B7):
- Atezolizumab + Bevacizumab (IMbrave150)
- Durvalumab + Tremelimumab (STRIDE, HIMALAYA)
Bleeding Risk Protocol (Mandatory)
- Upper GI endoscopy within 3 months before bevacizumab
- Band high-risk varices or start carvedilol
- Contraindication: Prior variceal bleed + bevacizumab
4. UK Outcomes & Equity: The BSG Call to Action
UK 1-year survival: ~50% vs Japan 70%. Why?
Barriers
- Late diagnosis
- Regional variation in MDT access
- Long transplant wait times
- Underuse of ablation
Solutions
- GP-led surveillance
- Mandatory regional HCC MDTs
- 4-week transplant referral
- Nurse-led ablation clinics
Conclusion: From Guideline to NHS Reality
The BSG 2025 HCC guidelines are a pragmatic revolution — turning global evidence into daily NHS practice. For clinicians, it’s your new decision tree. For patients, it’s a promise of earlier detection, safer treatment, and fairer access.
Original Source:
Suddle A, Reeves H, Marshall A, et al. British Society of Gastroenterology hepatocellular carcinoma guideline review: impact on the frontline. Frontline Gastroenterology. 2025;16(6):452-460. doi:10.1136/flgastro-2024-102927
Need Help with HCC Diagnosis or Treatment in the UK?
Our team can connect you with NHS hepatologists, arrange second opinions, or explore advanced options abroad.